Jazz Pharmaceuticals Completes Sale Of Its Women's Health Business To Meda
DUBLIN, Oct. 15, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the sale of its women's health business to Meda (an international specialty pharmaceutical company) for $95 million in cash.
The products included in the sale are Elestrin ® (estradiol gel), Gastrocrom ® (cromolyn sodium, USP), Natelle ® One (prenatal vitamin), AVC™ Cream (sulfanilamide), Gesticare ® DHA (prenatal multi-vitamin) and Urelle ® (urinary antiseptic).
For accounting purposes, the women's health business will be treated as a discontinued operation. More detail about the accounting impact of the transaction will be disclosed in pro forma financial statements filed on a Form 8-K and in the company's Form 10-Q for the quarter ended September 30, 2012.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products to meet unmet medical needs. The company's U.S. marketed products include: Xyrem ® (sodium oxybate), Erwinaze ™ (asparaginase Erwinia chrysanthemi), Prialt ® (ziconotide) intrathecal infusion, FazaClo ® (clozapine USP) HD and LD and Luvox CR ® (fluvoxamine maleate). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by an international division, EUSA Pharma. For further information, see http://www.jazzpharmaceuticals.com . SOURCE Jazz Pharmaceuticals plc
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
